ArticlePharmaceutics2019
Sulforaphane-Loaded Ultradeformable Vesicles as A Potential Natural Nanomedicine for the Treatment of Skin Cancer Diseases.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 97 citations in OpenAlex.
- Nanocarrier-Enabled Delivery of Glucosinolates for Skin Cancer Prevention and Therapy.The AAPS journal · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Article
- Review
- Article
- Nanodelivery Approaches of Phytoactives for Skin Cancers: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Preparation of Paeonol Ethosomes by Microfluidic Technology Combined with Gaussians and Evaluation of Biological Activity by Zebrafish.ACS omega · 2024Article
- Recent advances in nanomaterial-based drug delivery systems for melanoma therapy.ADMET & DMPK · 2024Review
- Gelled Liquid Crystal Nanocarriers for Improved Antioxidant Activity of Resveratrol.Gels (Basel, Switzerland) · 2023Article
- Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches.Molecular cancer · 2023Review
- Exploring Nanocarriers as Treatment Modalities for Skin Cancer.Molecules (Basel, Switzerland) · 2023Review
- Nanoparticles for Topical Application in the Treatment of Skin Dysfunctions-An Overview of Dermo-Cosmetic and Dermatological Products.International journal of molecular sciences · 2022Review
- Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment.Molecules (Basel, Switzerland) · 2022Review
- Polysaccharide-Based Transdermal Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Membrane Vesicles for Nanoencapsulated Sulforaphane Increased Their Anti-Inflammatory Role on an In Vitro Human Macrophage Model.International journal of molecular sciences · 2022Article
- Lipid-Based Nanovesicular Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2021Review
- Nanoencapsulation of sulforaphane in broccoli membrane vesicles and theirPharmaceutical biology · 2021Article
- Dietary supplementation with sulforaphane ameliorates skin aging through activation of the Keap1-Nrf2 pathway.The Journal of nutritional biochemistry · 2021Article
- Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulforaphane is a multi-action drug and its anticancer activity is the reason for the continuous growth of attention being paid to this drug. Sulforaphane shows an in vitro antiproliferative activity against melanoma and other skin cancer diseases. Unfortunately, this natural compound cannot be applied in free form on the skin due to its poor percutaneous permeation determined by its physico-chemical characteristics. The aim of this investigation was to evaluate ethosomes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.